<DOC>
	<DOC>NCT00700635</DOC>
	<brief_summary>To explore the potential benefit of the administration of Menactra vaccine as a two-dose regimen to children. Primary Objective: To assess, by age group, the immune response to Menactra vaccine after each vaccine injection.</brief_summary>
	<brief_title>Dose Comparison Study of Menactra® in US Children</brief_title>
	<detailed_description>This is an open-label trial designed to explore the immune response to a two-dose schedule of Menactra vaccine compared with a standard one-dose schedule in children.</detailed_description>
	<mesh_term>Meningitis</mesh_term>
	<mesh_term>Meningococcal Infections</mesh_term>
	<criteria>Inclusion Criteria : Aged 2 to &lt; 11 years on the day of inclusion. Provision of assent form signed by the subject (depending on age) and informed consent form signed by the parent(s) or another legally acceptable representative. Subject and parent/legal guardian able to attend all scheduled visits and comply with all trial procedures. Exclusion Criteria : Previous vaccination against meningococcal disease with either the trial vaccine or another vaccine. Participation in the active (i.e., treatment) portion of another clinical trial investigating a vaccine, drug, medical device, or a medical procedure in the 4 weeks preceding the first trial vaccination. Planned participation in another clinical trial during the present trial period. Known or suspected congenital or acquired immunodeficiency, immunosuppressive therapy such as anticancer chemotherapy or radiation therapy within the preceding 6 months, or longterm systemic corticosteroids therapy. Suspected or known systemic hypersensitivity to any of the vaccine components, or history of a lifethreatening reaction to a product containing any of the substances present in the study vaccine . Chronic illness at a stage that could interfere with trial conduct or completion, in the opinion of the Investigator. Receipt of blood or bloodderived products in the past 3 months. Received any vaccine (other than desensitization therapy for allergies or influenza vaccine within 2 weeks before vaccination) in the 4 weeks preceding the first trial vaccination. Planned receipt of any vaccine within the 4 weeks following any trial vaccination(s). Known human immunodeficiency virus (HIV), hepatitis B surface antigen (HBs antigen), or hepatitis C seropositivity. History of invasive meningococcal infection (confirmed either clinically, serologically, or microbiologically). Thrombocytopenia, coagulation disorder, or anticoagulant use in the 3 weeks preceding inclusion contraindicating intramuscular (IM) vaccination. Anticipated to receive oral or injected antibiotic therapy within the 72 hours prior to any of the trial blood draws. Personal or family history of GuillainBarré Syndrome (GBS). Any condition which, in the opinion of the Investigator, would pose a health risk to the subject or interfere with the evaluation of the vaccine.</criteria>
	<gender>All</gender>
	<minimum_age>2 Years</minimum_age>
	<maximum_age>10 Years</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>Meningitis; Meningococcal infection, Neisseria meningitidis</keyword>
</DOC>